Clinical value of serum anti-mullerian hormone and inhibin B in prediction of ovarian response in patients with polycystic ovary syndrome

SummaryThe present study aimed to investigate the clinical value of serum anti-mullerian hormone (AMH) and inhibin B (INHB) in predicting the ovarian response of patients with polycystic ovary syndrome (PCOS). A total of 120 PCOS patients were enrolled and divided into three groups in terms of the ovarian response: a low-response group (n=36), a normal-response group (n=44), and a high-response group (n=40). The serum AMH and INHB levels were measured by enzyme-linked immunosorbent assay (ELISA). The follicle stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2) levels were determined by chemiluminescence microparticle immunoassay. The correlation of the serum AMH and INHB levels with other indicators was analyzed. A receiver operating characteristic (ROC) curve was established to analyze the prediction of ovarian response by AMH and INHB. The results showed that there were significant differences in age, body mass index (BMI), FSH, total gonadotropin-releasing hormone (GnRH), LH, E2, and antral follicle counts (AFCs) between the groups (P<0.05). The serum AMH and INHB levels were increased significantly with the ovarian response of PCOS patients increasing (P<0.05). The serum AMH and INHB levels were negatively correlated with the age, BMI, FSH level, Gn, and E2 levels (P<0.05). They were positively correlated with the LH levels and AFCs (P<0.05). ROC curve analysis of serum AMH and INHB in prediction of a low ovarian response showed that the area under the ROC curve (AUC) value of the serum AMH level was 0.817, with a cut-off value of 1.29 ng/mL. The sensitivity and specificity were 71.2% and 79.6%, respectively. The AUC value of serum INHB was 0.674, with a cut-off value of 38.65 ng/mL, and the sensitivity and specificity were 50.7% and 74.5%, respectively. ROC curve analysis showed when the serum AMH and INHB levels were used to predict a high ovarian response, the AUC value of the serum AMH level was 0.742, with a cut-off value of 2.84 ng/mL, and the sensitivity and specificity were 72.7% and 65.9%, respectively; the AUC value of the serum INHB level was 0.551 with a cut-off of 45.76 ng/mL, and the sensitivity and specificity were 76.3% and 40.2%, respectively. It was suggested the serum AMH and INHB levels have high clinical value in predicting the ovarian response of PCOS patients.

[1]  B. Fauser,et al.  Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. , 2004, Molecular human reproduction.

[2]  R. Azziz,et al.  Diagnosis, phenotype, and prevalence of polycystic ovary syndrome. , 2006, Fertility and sterility.

[3]  S. Andric,et al.  In vivo blockade of α1-adrenergic receptors mitigates stress-disturbed cAMP and cGMP signaling in Leydig cells. , 2014, Molecular human reproduction.

[4]  F. Petraglia,et al.  Inhibins in female and male reproductive physiology: role in gametogenesis, conception, implantation and early pregnancy. , 2005, Human reproduction update.

[5]  C. Laskin,et al.  Anti-Mullerian hormone: reality check. , 2014, Human reproduction.

[6]  H. Cook-Andersen,et al.  Decreased inhibin B responses following recombinant human chorionic gonadotropin administration in normal women and women with polycystic ovary syndrome. , 2014, Fertility and sterility.

[7]  W. Robertson,et al.  Day 5 inhibin B levels in a treatment cycle are predictive of IVF outcome. , 2002, Human reproduction.

[8]  J. Visser,et al.  Anti-Müllerian hormone: a new marker for ovarian function. , 2006, Reproduction.

[9]  N. Knowlton,et al.  Correlation of ovarian reserve tests with histologically determined primordial follicle number. , 2011, Fertility and sterility.

[10]  R. Casamitjana,et al.  Inhibin, follicle-stimulating hormone, and age as predictors of ovarian response in in vitro fertilization cycles stimulated with gonadotropin-releasing hormone agonist-gonadotropin treatment. , 1996, American journal of obstetrics and gynecology.

[11]  P. Bossuyt,et al.  Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. , 2013, Human reproduction update.

[12]  S. Whitehead,et al.  Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. , 2007, The Journal of clinical endocrinology and metabolism.

[13]  J. Visser,et al.  Anti-Müllerian hormone and folliculogenesis , 2005, Molecular and Cellular Endocrinology.

[14]  F. Broekmans,et al.  AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. , 2011, Human reproduction update.

[15]  K. Loveland,et al.  All in the family: TGF-β family action in testis development , 2006 .

[16]  G. Lambert-Messerlian,et al.  Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. , 1997, Fertility and sterility.

[17]  A. Durlinger,et al.  Anti-Müllerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. , 2002, Endocrinology.

[18]  A. Volpe,et al.  Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). , 2010, Human reproduction update.

[19]  T. Kutlu,et al.  The role of inhibin B as a basal determinant of ovarian reserve , 2003, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[20]  D. Seifer,et al.  Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. , 2004, Fertility and sterility.

[21]  A. Armeni,et al.  Sibutramine administration decreases serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome. , 2012, European journal of obstetrics, gynecology, and reproductive biology.

[22]  C. Lambalk,et al.  Testing ovarian reserve to predict age at menopause. , 2009, Maturitas.